Achieving Localised Delivery With Magnetic Vectoring - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Achieving Localised Delivery With Magnetic Vectoring
Charles E. Seeney tells us about the possibilities of nanotechnology and magnetism, and how a novel approach could improve localised drug delivery.


Pharmaceutical Technology Europe


Q. What is magnetic vectoring and why is this approach different from other delivery technologies?


Magictorch/ Magictorch/Getty Images
The concept of nanomagnetic therapy is based on the unique properties of magnetically responsive nanoparticles (MNP) responding to an applied magnetic field gradient. MNP are nanoscale, ferromagnetic materials that present spontaneous magnetisation in an applied magnetic field, and exhibit rapid demagnetisation with no remanence when the field is removed. This superparamagnetism is, in essence, a magnetic (or biomagnetic as I like to call it) on–off switch that can be exploited in numerous ways to offer enhanced/advanced therapeutic options, ranging from early-stage diagnostics to medical imaging to localised drug delivery.

The idea of using magnetic forces to enhance treatment therapies and improve therapeutic benefit has been around for many decades, but advances in this area are only now being realised thanks to the emerging field of nanomedicine and the application of nanotools to treatment modalities.


Charles E. Seeney
Q. What is the potential for magnetic delivery systems in medical therapies? What progress have pharma companies already made in this area?

Magnetic-based therapies can be traced back through several centuries and, for the interested, an excellent historical review is presented in Magnetism in Medicine (1). Recent progress, with the development of smaller and more powerful magnets leading to highly functional miniaturised devices, has seen the expansion of magnetic applications across a spectrum of treatment methodologies that are being investigated in the clinic, such as cell separation, magnetic resonance imaging, enhanced gene transfer, localised targeted delivery of therapeutics or magnetically induced hyperthermia and early-stage cancer diagnostics. Recently, magnetic nanoparticles have also been applied to applications in tissue engineering and are being used to construct multilayered cell structures. In addition, applications in areas of allergy diagnosis are under study.

One significant development is magnetically guided catheter technology, which is now used in cardiac stimulation and ablation therapy (2, 3). Although this is considered to be an invasive therapy, it offers the potential for site-specific drug delivery. In cardiac ablation therapy for the treatment of atrial fibrillation, where surgical procedures are indicated, a cardiac interventional workstation is used to navigate a catheter over short distances to the site of the arrhythmia. An extension of this procedure is the delivery of therapeutics to the site as well, being held in place using MNPs.

The advent of functionalised MNP, such as ferromagnetic materials with superparamagnetic properties, has further opened new opportunities within the field of nanomedicine for targeted therapies. Progress in the development of nanomagnetic treatment modalities can generally be described as following two paths; one is based on implanted MNPs, where the oscillation of the particles provides the benefit, while the second path uses MNPs as vehicles or carriers for targeted therapeutics.

Only a limited number of nanoscale therapeutic formulations demonstrating both enhanced solubility and drug targeting properties have received FDA approval (5). To date, however, nanomagnetic therapies have only reached limited clinical use (4). One drug targeting system for doxorubicin using micromagnetic (as opposed to nanoscale) particles, developed in the late 1990s, failed in clinical trials (6). Although presenting much potential, nanoscale biomaterials have been slow to develop into clinical applications. This can be attributed to a variety of reasons. The first is generally related to the physics of nanoparticles and the development of characterisation methods for understanding and preventing behaviour, such as particle interactions and agglomeration in the physiological environment. A second reason relates to methods for defining and understanding the biodistribution and specificity of nanoscale therapeutic formulations, which remains imperfect because of the body's complex response to nanoscale materials. Thirdly, it i difficult to find a delivery methodology for site-specific or organ-specific targeting.

Recent advances in nanomaterial preparation and characterisation indicate that it is possible to overcome these limitations by using MNPs as drug carriers to improve drug localisation and overcoming cytotoxic effects. While magnetic targeting is not likely to be effective in all situations, with further development it should provide another tool for disease treatment.

Although commercial success has been limited so far, the application of nanomagnetics to drug targeting opens a range of new opportunities for enhanced therapeutic performance, as described with magnetic vectoring (7, 8), magnetofection (9), magnetic hyperthermia (10) or with tissue vibration (11). These technologies are all at varying stages of development, but could deliver new therapeutic options for physicians and patients in the coming years.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here